Introduction
Protein S (reviewed in ref. 1 40% circulates free and ~60% is bound to the complement regulatory factor C4b-binding protein (C4BP). 2 Only C4BP molecules with a _-chain (C4BP-beta + ) bind protein S and, given the high affinity of this interaction (Kd =0.1 nM), 2 all C4BP-beta + present in plasma (~200 nM) is complexed with protein S. 3 Protein S is a potent anticoagulant protein that down-regulates thrombin formation via two mechanisms. 4 On one hand it stimulates the proteolytic inactivation of coagulation factors (F) Va and VIIIa by activated protein C (APC), 5 and on the other hand it enhances the inhibition of FXa by tissue factor pathway inhibitor (TFPI). [6] [7] [8] Although free protein S is the most active form, recent reports indicate that the protein S-C4BP complex also exhibits APC-and TFPI-cofactor activities. 6, 9 Hereditary protein S deficiency is a rare coagulation disorder associated with an increased risk of venous thrombosis. 10, 11 It usually occurs as a partial (heterozygous) deficiency and segregates as an autosomal dominant trait. Presently, more than 200 mutations that impair protein S synthesis and/or function have been described in the protein S gene (PROS1), and large deletions/duplications within the PROS1 locus have been identified as a relatively common cause of protein S deficiency. 12, 13 Based on protein S antigen and (APC-cofactor) activity levels, protein S deficiency is classified as type I (low total and free antigen, reduced activity), type II (normal total and free antigen, reduced activity) and type III (normal total antigen, reduced free antigen and activity). However, since protein S levels are strongly influenced by age, sex and hormonal status, 14 as well as by several acquired conditions, the diagnosis of protein S deficiency states based on protein S levels is far from straightforward in practice.
Type I and type III deficiencies account for 95% of protein S-deficient patients and often occur together in the same family as phenotypic variants of the same genetic defect (mixed type I/III deficiency). 15 The reasons for the different phenotypic expression are poorly understood, but the age-dependent increase in total protein S is thought to play a role, as type III protein S-deficient family members tend to be older than their type I deficient relatives. 16 Differently, other families with protein S deficiency only express the type III phenotype (pure type III deficiency). This type of protein S deficiency is often, but not always, 17 associated with the PROS1 Ser 460 !Pro (Heerlen) mutation. 18 Although protein S deficiency, and particularly low levels of free protein S, 19, 20 are an established risk factor for venous thrombosis, risk estimates differ widely among studies, possibly reflecting the different severity of the underlying molecular defects. 21 Moreover, the few epidemiological studies that distinguish between type I and type III deficiencies are rather contradictory with respect to the thrombosis risk associated with type III deficiency, which was found to be none, 22 the same as in type I deficiency 23 or intermediate. 24 To clarify this issue, we have re-evaluated the risk of thrombosis associated with type I and type III protein S-deficiencies by Kaplan-Meier analysis of a large cohort of protein S-deficient families. In support of our findings, we present a detailed characterization of type I and type III protein S-deficient plasma based on the measurement of coagulation factor levels and ad hoc thrombin generation assays. 25, 26 Protein S deficiency was defined on the basis of free protein S levels, 27,28 applying a cut-off of 65%. The type of deficiency was assigned according to total protein S levels, using a cut-off of 70%. These cut-offs were based on the variation of total and free protein S levels in a population of 140 healthy individuals, irrespective of age and sex. However, application of sex-specific cut-offs for total and free protein S levels hardly affected the classification of the subjects and did not change the results described in this paper.
Design and Methods

Study population
Plasma samples for functional studies and blood cells for DNA extraction could be obtained for 23 of the above-mentioned 30 families. Blood samples were collected from probands and consenting family members for a total of 151 subjects. Patients on oral anticoagulant therapy (n=13) and women taking oral contraceptives (n=3) or hormone replacement therapy (n=3) at the time of blood collection were subsequently excluded, leaving 132 individuals available for study (Table 1 ). All participants provided informed consent to the study, which was carried out in accordance with the Helsinki protocol.
Blood collection and plasma preparation
Venous blood was drawn in 0.129 M sodium citrate (1:9 vol/vol) and plateletpoor plasma was prepared by centrifugation at 2000 µg for 10 min. Plasma was aliquoted, snap-frozen and stored at -80 °C until use. Buffy coats were stored at -20 °C for later DNA isolation.
Measurement of plasma factor levels
In-house ELISAs were used to measure the plasma antigen levels of total, 29 free 30 and C4BP-bound protein S, 9 as well as full-length TFPI. 31 Prothrombin levels were determined with a chromogenic assay, as previously described. 32 Antithrombin activity levels were determined using the Coamatic" Antithrombin kit (Chromogenix, Mölndal, Sweden). The levels of all factors were expressed as percentage of normal pooled plasma.
Thrombin generation measurements
Thrombin generation was measured with the Calibrated Automated Thrombogram (CAT) method. 33 Coagulation was initiated with tissue factor (TF, To probe the activity of the APC/protein S system, thrombin generation was initiated with 6.8 pM TF and 30 µM phospholipids in the absence and presence of 5 nM human APC (Kordia Life Sciences, Leiden, The Netherlands), as described. 32 The outcome of the assay was expressed as the ratio of the endogenous thrombin potentials (ETPs) obtained in the presence and absence of APC, and normalized against the ETP ratio of normal pooled plasma measured in parallel (normalized APC-sensitivity ratio, nAPCsr). Since protein S is a major determinant of this assay, 34 the nAPCsr is an indirect measure of the APC-dependent activity of protein S. The nAPCsr varies between 0 and 10 and increases as the plasma level of protein S (and hence its APCcofactor activity) decreases.
To quantify the activity of the TFPI/protein S system, thrombin generation was initiated with 1.36 pM TF and 30 µM phospholipids in the absence and presence of neutralizing antibodies against protein S (270 !g/ml polyclonal IgG; DAKO, Glostrup, Denmark) or TFPI (64 µ g/mL monoclonal IgG1; Sanquin, Amsterdam, The Netherlands), essentially as described. 31 To exclude any contribution of the APCdependent activity of protein S, these measurements were conducted in the presence of 100 µg/ml anti-protein C polyclonal antibodies (DAKO). Moreover, corn trypsin inhibitor (CTI, Hematologic Technologies, Essex Junction VT, USA) was added to a final concentration of 30 µg/mL to prevent contact activation. At the low TF concentration used in this assay, the height of the thrombin peak proved to be a more sensitive indicator of thrombin generation than the ETP and was therefore used as output parameter. The ratio of the thrombin generation peaks obtained in the absence and presence of anti-protein S antibody (PS-ratio) is a measure of the TFPI-cofactor activity of protein S, while the ratio of the thrombin generation peaks obtained in the absence and presence of anti-TFPI antibody (TFPI-ratio) is a measure of the activity of the TFPI/protein S system as a whole. 31 Both ratios vary between 0 and 1 and increase as the TFPI-cofactor activity of protein S decreases.
Genetic analysis
Buffy coats were available for 110 of the 132 eligible participants. Genomic DNA was extracted using the Wizard ® Genomic DNA Purification kit (Promega, Madison WI, USA). PROS1 mutation screening was performed by PCR-mediated amplification of each exon (including splicing junctions) and >400 bp of the promoter region 35 followed by direct sequencing. PCR primers and conditions (available on request) were chosen such as to avoid co-amplification of the highly homologous protein S pseudogene. Selective amplification of PROS1 was verified by restriction analysis of the PCR products. Whenever a PROS1 mutation was identified, all family members were tested for carriership of that mutation by high-resolution agarose gel electrophoresis, restriction analysis or direct sequencing, as detailed in Table 2 . The PROS1 Heerlen genotype was determined by Rsa I-restriction analysis of exon 13.
In families without apparent mutation, the possibility of a large deletion was Carriership of the FV Leiden and prothrombin G20210A mutations was determined as previously described.
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Statistics
Kaplan-Meier analysis. Thrombosis-free survival was analyzed with the Kaplan-Meier method. The age at onset of the first thrombotic event for symptomatic individuals and the age at the time of inclusion in the study for asymptomatic subjects were used to evaluate the thrombosis-free survival time. Thrombosis-free survival was compared between normal, type I protein S-deficient and type III protein S-deficient individuals, with probands included or excluded, and in probands only. The analysis was done including all patients or only patients whose first thrombotic event had been deep-vein thrombosis and/or pulmonary embolism. Differences between the curves
were assessed with the log-rank test. To evaluate the risk of thrombosis associated with protein S deficiency, KaplanMeier analysis was performed. As expected, the cumulative proportion of thrombosisfree individuals was higher (P<0.001) in the normal group than in the protein Sdeficient group ( Figure 1A,B) . However, no significant difference in thrombosis-free survival was observed between type I and type III protein S-deficient individuals in the whole cohort (probands and family members, Figure 1A ), nor after exclusion of probands ( Figure 1B ) or in probands only ( Figure 1C ). Results did not change when survival analysis was restricted to patients whose first thrombotic event had been deepvein thrombosis and/or pulmonary embolism or when males and females were analyzed separately (data not shown).
Results
Clinical evaluation
Laboratory evaluation: characteristics of the study population
Plasma factor levels and thrombin generation were measured in a random subset of the population used for Kaplan-Meier analysis (23 families Genotyping for the FV Leiden mutation identified 8 heterozygous carriers in three different families. Twelve individuals belonging to 5 different families were heterozygous for the prothrombin G20210A mutation.
Plasma factor levels
Plasma levels of protein S (total, free and C4BP-bound), prothrombin, antithrombin and full-length TFPI were measured in all subjects and compared between groups ( Figure 2 ). Total protein S levels ( Figure 2A) Prothrombin levels ( Figure 2D ) did not differ between normal (92.5±18.7%) and type I deficient individuals (88.8±12.0%), but they were significantly elevated in type III deficient individuals (104.1±16.0%, P=0.011 and P=0.001 vs. normal and type I deficient individuals, respectively). This difference persisted after exclusion of the prothrombin G20210A mutation carriers. Antithrombin levels ( Figure 2E ) were similar in all three groups. Finally, full-length TFPI levels ( Figure 2F) were not different between normal (122.9±47.7%) and type III deficient individuals (121.3±31.4%), but were significantly reduced in type I deficient individuals (76.9±32.5%, P<0.001) as observed and explained elsewhere. 37 All inter-group differences in plasma factor levels persisted after correction for age and sex.
Plasma levels of coagulation factors and inhibitors were correlated in the study population. The strongest correlations were observed between total, free and bound protein S (total/free: r=0.885; total/bound: r=0.413; free/bound: r=0.434; P<0.001 for all three correlations), total protein S and full-length TFPI (r=0.607, P<0.001), and total protein S and prothrombin (r=0.371, P<0.001). These correlations remained significant when normal and protein S-deficient individuals were analyzed separately.
APC-cofactor activity of protein S
To quantify the activity of the APC/protein S system, thrombin generation was measured at 6.8 pM TF in the absence and presence of APC, and the nAPCsr was calculated. Since FV Leiden strongly influences this assay, FV Leiden carriers were excluded from the analysis.
Despite a large inter-individual variability, thrombin generation started earlier (shorter lag time) and was higher in protein S-deficient plasma than in normal plasma, both in the absence and presence of APC (Table 1 Supplemental Material). In the absence of APC ( Figure 3A) , there was no difference between the ETPs of normal and type I deficient individuals, but type III deficient individuals had significantly higher ETP values (P$0.001). In the presence of APC (Figure 3B ), the ETPs of type I and type III deficient individuals were similar and ~3.5 higher than those of normal individuals (P <0.001). As a consequence, the nAPCsr ( Figure 3C ), was highest in type I deficient plasma, slightly lower in type III deficient plasma (P=0.057) and much lower in normal plasma (P<0.001). Thrombotic patients had a higher nAPCsr than healthy relatives, both in the type I (6.36±1.38 vs. 5.77±1.37) and in the type III (5.59±2.04 vs.
4.97±1.83) deficiency groups, but these differences did not reach statistical significance.
To interpret these results, the effects of age, sex and the levels of prothrombin, 
TFPI-cofactor activity of protein S
The activity of the TFPI/protein S system was quantified by measuring thrombin generation at 1.36 pM TF in the absence and presence of neutralizing antibodies against protein S (alphaPS) or TFPI (alphaTFPI) and by calculating the PS-and TFPI-ratios. Also in this case FV Leiden carriers were excluded.
Thrombin generation in the absence of antibodies was faster and higher in protein S-deficient plasma than in normal plasma (Table 2 Supplemental Material).
However, this difference largely disappeared in the presence of antibodies, only the lag time remaining slightly but significantly shorter in protein S-deficient plasma (Table 2 Supplemental Material). Also in this test, a large inter-individual variability was observed. In the absence of antibodies ( Figure 4A ), the peak height was virtually identical between type I and type III deficient individuals, and higher than in normal individuals (p"0.011). Addition of alphaPS, and even more so addition of alphaTFPI, caused an increase in thrombin generation, due to the partial (alphaPS) or complete (alphaTFPI) inhibition of the TFPI/protein S system. In the presence of alphaPS (Figure 4B ), the peak height was similar between normal and type III deficient individuals, while type I deficient individuals had slightly higher thrombin peaks, possibly due to their lower TFPI levels.
In the presence of the alphaTFPI antibody ( Figure 4C ), normal and type I deficient plasmas yielded similar peak heights, which however were lower than in type III deficient plasma (P=0.022 and P=0.010, respectively). The PS-ratio ( Figure 4D ) and TFPI-ratio ( Figure 4E ) increased progressively from normal to type III and type I deficient plasma.
However, the difference between type I and III deficient individuals was only significant for the TFPI-ratio (P=0.034).
Multiple regression analysis revealed that the peak height in the absence of antibodies was dependent not only on free protein S (B=-13.4 nM/10%, P=0.021) and TFPI (B=-5.7 nM/10%, P<0.001), but also on age (B=0.8 nM/year, P=0.035) and prothrombin (B=8.3 nM/10%, P=0.023), thereby accounting for the equally elevated peaks in type I and type III deficient individuals. The higher peak +_PS of type I deficient individuals was attributable their lower TFPI levels (B=-6.8 nM/10%, P=0.002), whereas the higher age (B=1.1 nM/year, P<0.001) and prothrombin level (B=17.5 nM/10%, P<0.001) of type III deficient individuals were responsible for their elevated peak +_TFPI .
Relationship between nAPCsr and TFPI-ratio
The nAPCsr and the TFPI-ratio reflect the activities of the APC/protein S and TFPI/protein S systems, respectively. Both were elevated in protein S-deficient individuals, especially in those with type I deficiency, in line with the respective protein S levels.
Multiple regression analysis showed that free protein S and full-length TFPI levels were major determinants of both the nAPCsr (B=-0.37/10% protein S, P<0.024; B=-0.10/10% TFPI, P=0.007) and the TFPI-ratio (B=-0.06/10% protein S, P=0.011; B=-0.02/10% TFPI, P<0.001). Accordingly, the nAPCsr and the TFPI-ratio were highly correlated in the population (r=0.629, P<0.001). The correlation between nAPCsr and TFPI-ratio was also present within the normal (r=0.663, P<0.001) and type I deficiency (r=0.510, p<0.001) groups, as well as within the type III deficiency group (r=0.501, p=0.034) after exclusion of a single outlier.
PROS1 mutation screening
Due to the availability of genomic DNA from at least one protein S-deficient family member, PROS1 mutation screening was possible in 20 of the 23 families. By sequencing the coding region (including splicing junctions) and the proximal promoter, a PROS1 mutation was identified in 14 families (Table 2 ). In the six families where no mutation was detected, MLPA analysis was performed to check for the presence of major rearrangements of the PROS1 gene. Two large deletions, spanning exons 2-15 and 9-11, respectively, were identified in two different families ( Figure 5 ).
When the genetic screening was extended to family members, the respective mutation or deletion was identified in 56/58 (96.5%) individuals classified as protein Sdeficient on the basis of protein S levels and in 2/30 (6.7%) of individuals classified as normal. The PROS1 Heerlen mutation was present in 3 related individuals, two with type III deficiency and one with protein S levels within the normal range. All mutations were in the heterozygous state. In all mixed type I/III families (except in the family with the Heerlen mutation), the same mutation accounted for type I as well as type III deficient members.
Interestingly, protein S-deficient individuals from families with a PROS1 mutation or deletion had lower protein S levels and higher nAPCsr, PS-ratio and TFPIratio than protein S-deficient individuals from families without an identifiable PROS1 defect (data not shown). Thrombosis-free survival was not different between protein Sdeficient individuals with and without an identifiable PROS1 defect, but it was significantly reduced in carriers of a PROS1 mutation or deletion as compared to noncarriers (log-rank, p=0.039).
Discussion
Although the thrombotic predisposition associated with protein S deficiency was recognized as early as 1984, 10,11 accurate risk estimates have been hindered by the difficulty of correctly diagnosing protein S deficiency. Currently, type I protein S deficiency is generally considered a risk factor for venous thrombosis, while conflicting results have been reported for type III deficiency. [22] [23] [24] In the present study we have re-evaluated the thrombosis risk associated with type I and type III protein S deficiencies by Kaplan-Meier analysis of a large cohort of protein S-deficient families. Our data indicate that hereditary type III protein S deficiency is a risk factor for venous thrombosis and that it confers a similar risk as type I protein S deficiency (Figure 1 ). Although type III deficient individuals were older than type I deficient individuals and advancing age is also a risk factor for thrombosis, the age at onset of thrombosis was not different between the two groups.
To account for this finding, genetic and functional studies were performed in 23 families with type I and/or type III protein S deficiency (Table 1) . Genetic screening was possible in 20 families and yielded 12 PROS1 mutations (3 novel) in 14 families (Table 2) . Moreover, large PROS1 deletions were present in two families ( Figure 5 ), in line with the recent report that major rearrangements of the PROS1 gene are relatively common among mutation-negative protein S-deficient individuals. 13 When family members were tested for carriership of the mutation found in the respective proband, an excellent co-segregation between PROS1 genotype and protein S levels was observed.
This not only confirms the causal role of the identified mutations, but also indicates that the free protein S level cut-off used to define protein S deficiency is appropriate and reliable. 28 Remarkably, the only two mutation-positive individuals who were classified as normal on the basis of their protein S levels carried the Thr 103 !Asn mutation, which has been associated with qualitative (type II) protein S deficiency in another study. 38 However, the nAPCsr and TFPI-ratio of our two carriers were within the respective normal ranges.
For functional studies, the population was divided in three groups (normal, type I deficient and type III deficient) based on the levels of total and free protein S. In line with other reports, 16 ,17 type III protein S-deficient individuals were older than their normal and type I deficient relatives. Moreover, they had higher protein S (total, free and bound), prothrombin and TFPI levels than type I deficient individuals ( Figure 2 ).
Interestingly, a recent study reported that type III deficient individuals have elevated protein C levels as well. 17 Since the levels of all these factors increase with age, 34 our data support the hypothesis that type III deficient individuals from families with mixed type I/III deficiency start out as type I deficient, but become type III deficient later in life because of the age-related increase in total protein S levels. 16 If this is the case, not only protein S, protein C and prothrombin, but also other age-dependent coagulation factors might be increased in type III deficient plasma. Differently, type I (but not type III) deficient individuals had markedly reduced TFPI levels, in line with the observation that the levels of protein S and TFPI are highly correlated in plasma. 37, 39 These additional abnormalities in plasma factor levels may synergize with the low protein S levels to aggravate the hypercoagulable state associated with type I and type III protein S deficiencies and underscore the importance of global phenotyping tests to evaluate the associated thrombosis risk.
Despite the expectation (based on protein S and TFPI levels) that type I deficient plasma would be more procoagulant than type III deficient plasma, thrombin generation assays sensitive to the APC-and TFPI-cofactor activities of protein S detected only a minor difference between type I and type III deficient plasmas ( Figures   3C and 4D,E) . Remarkably, the slightly lower nAPCsr of type III deficient individuals as compared to type I deficient individuals was not due to a lower ETP +APC , but to a higher ETP -APC (Figure 3) . Similarly, their lower TFPI-ratio was not due to a lower peak -Ab , but to a higher peak +_TFPI (Figure 4) . Multiple regression analysis pointed at age and prothrombin, in addition to free protein S, as the major determinants of elevated thrombin generation in type III deficient plasma. While high prothrombin levels are known to cause APC-resistance, 32 and to interfere with plasma assays that probe the APC-independent (TFPI-dependent) anticoagulant activity of protein S, 40 age might act by elevating the levels of several coagulation factors. 34 Since both the nAPCsr and the TFPI-ratio reflect protein S as well as TFPI levels, they were highly correlated in the population.
As the nAPCsr is a marker for the risk of venous thrombosis, 41 the data presented in Figure 3C support the outcome of the Kaplan-Meier analysis and confirm that type I and type III protein S deficiencies confer similar thrombosis risks. This finding is in line with a previous study, 23 but contrasts with other studies where the risk of thrombosis associated with type III protein S deficiency was found to be half than in type I deficiency 24 or not elevated at all. 22 A possible explanation for these discrepancies may be the population selection criteria, as it has been reported that type III deficient individuals from pure type III deficient families are not at risk for thrombosis, while those from mixed type I/type III deficient families are. 24 Also, no risk is generally attributed to the PROS1 Heerlen mutation. 18 In this respect, it is important to point out that in our study type III deficiency was defined solely on the basis of protein S levels, irrespective of mutational status. Due to the small sample size, 49, 50 BstX I-restriction cDNA numbering according to Schmiedel et al. 1990 . 51 del, deletion; ins, insertion; NMD, nonsense-mediated decay; *mutagenic primer needed to introduce restriction site. 
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